151 related articles for article (PubMed ID: 20577877)
21. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.
Röpke M; Hald J; Guldberg P; Zeuthen J; Nørgaard L; Fugger L; Svejgaard A; Van der Burg S; Nijman HW; Melief CJ; Claesson MH
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14704-7. PubMed ID: 8962118
[TBL] [Abstract][Full Text] [Related]
22. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.
Stuber G; Leder GH; Storkus WT; Lotze MT; Modrow S; Székely L; Wolf H; Klein E; Kärre K; Klein G
Eur J Immunol; 1994 Mar; 24(3):765-8. PubMed ID: 8125143
[TBL] [Abstract][Full Text] [Related]
23. CD4+ T helper responses in squamous cell carcinoma of the head and neck.
Chikamatsu K; Sakakura K; Yamamoto T; Furuya N; Whiteside TL; Masuyama K
Oral Oncol; 2008 Sep; 44(9):870-7. PubMed ID: 18221909
[TBL] [Abstract][Full Text] [Related]
24. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.
McArdle SE; Rees RC; Mulcahy KA; Saba J; McIntyre CA; Murray AK
Cancer Immunol Immunother; 2000 Oct; 49(8):417-25. PubMed ID: 11043848
[TBL] [Abstract][Full Text] [Related]
25. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck.
Visus C; Ito D; Amoscato A; Maciejewska-Franczak M; Abdelsalem A; Dhir R; Shin DM; Donnenberg VS; Whiteside TL; DeLeo AB
Cancer Res; 2007 Nov; 67(21):10538-45. PubMed ID: 17974998
[TBL] [Abstract][Full Text] [Related]
26. Wildtype p53-specific antibody and T-cell responses in cancer patients.
Pedersen AE; Stryhn A; Justesen S; Harndahl M; Rasmussen S; Donskov F; Claesson MH; Pedersen JW; Wandall HH; Svane IM; Buus S
J Immunother; 2011; 34(9):629-40. PubMed ID: 21989411
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.
Barfoed AM; Petersen TR; Kirkin AF; Thor Straten P; Claesson MH; Zeuthen J
Scand J Immunol; 2000 Feb; 51(2):128-33. PubMed ID: 10652158
[TBL] [Abstract][Full Text] [Related]
28. Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas.
Visus C; Ito D; Dhir R; Szczepanski MJ; Chang YJ; Latimer JJ; Grant SG; DeLeo AB
Cancer Immunol Immunother; 2011 Jul; 60(7):919-29. PubMed ID: 21409596
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.
Nikitina EY; Clark JI; Van Beynen J; Chada S; Virmani AK; Carbone DP; Gabrilovich DI
Clin Cancer Res; 2001 Jan; 7(1):127-35. PubMed ID: 11205900
[TBL] [Abstract][Full Text] [Related]
30. Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line.
Würtzen PA; Pedersen LO; Poulsen HS; Claesson MH
Int J Cancer; 2001 Sep; 93(6):855-61. PubMed ID: 11519048
[TBL] [Abstract][Full Text] [Related]
31. P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells.
Chikamatsu K; Albers A; Stanson J; Kwok WW; Appella E; Whiteside TL; DeLeo AB
Cancer Res; 2003 Jul; 63(13):3675-81. PubMed ID: 12839958
[TBL] [Abstract][Full Text] [Related]
32. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.
Tokunaga N; Murakami T; Endo Y; Nishizaki M; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2005 Feb; 11(3):1312-8. PubMed ID: 15709203
[TBL] [Abstract][Full Text] [Related]
33. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells.
Kao H; Marto JA; Hoffmann TK; Shabanowitz J; Finkelstein SD; Whiteside TL; Hunt DF; Finn OJ
J Exp Med; 2001 Nov; 194(9):1313-23. PubMed ID: 11696596
[TBL] [Abstract][Full Text] [Related]
34. Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells.
Xie TX; Zhou G; Zhao M; Sano D; Jasser SA; Brennan RG; Myers JN
Laryngoscope; 2013 Jun; 123(6):1416-23. PubMed ID: 23625637
[TBL] [Abstract][Full Text] [Related]
35. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer.
McGregor JM; Harwood CA; Brooks L; Fisher SA; Kelly DA; O'nions J; Young AR; Surentheran T; Breuer J; Millard TP; Lewis CM; Leigh IM; Storey A; Crook T
J Invest Dermatol; 2002 Jul; 119(1):84-90. PubMed ID: 12164929
[TBL] [Abstract][Full Text] [Related]
36. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
37. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism.
Siddique M; Sabapathy K
Oncogene; 2006 Jun; 25(25):3489-500. PubMed ID: 16462765
[TBL] [Abstract][Full Text] [Related]
38. Targeted tumor cell death induced by autologous tumor-specific T lymphocyte recognition of wild-type p53-derived peptides.
Tsurushima H; Yoshii Y; Leong KW; Ohno T
J Neurooncol; 2006 Jan; 76(2):99-104. PubMed ID: 16132498
[TBL] [Abstract][Full Text] [Related]
39. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope.
Würtzen PA; Claesson MH
Int J Cancer; 2002 Jun; 99(4):568-72. PubMed ID: 11992547
[TBL] [Abstract][Full Text] [Related]
40. Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer.
Ferriès E; Connan F; Pagès F; Gaston J; Hagnéré AM; Vieillefond A; Thiounn N; Guillet J; Choppin J
Hum Immunol; 2001 Aug; 62(8):791-8. PubMed ID: 11476902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
